International Clinical Trial: Trastuzumab and pertuzumab in combination with eribulin mesylate as neoadjuvant therapy for early or locally advanced HER2-positive breast cancer: a prospective, single-arm, phase II clinical trial

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120346) titled 'Trastuzumab and pertuzumab in combination with eribulin mesylate as neoadjuvant therapy for early or locally advanced HER2-positive breast cancer: a prospective, single-arm, phase II clinical trial' on March 12.

Study Type: Interventional study

Study Design: Non randomized control

Primary Sponsor: The First Hospital of Jilin University

Condition: Breast Cancer

Recruitment Status: Recruiting

Phase: 4

Date of First Enrollment: 2025-12-23

Target Sample Size: Treatment Group:40;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=302162

Published by HT Dig...